Walleye Capital’s Anavex Life Sciences AVXL Stock Holding History

Walleye Capital’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$125K	Buy	40,600 +5,600	+16%	+$24.3K	﹤0.01%	3579
2025 Q4	$125K	Buy	+35,000	New	+$214K	﹤0.01%	3777
2025 Q2	–	Sell	-11,400	Closed	-$97.8K	–	4495
2025 Q1	$97.8K	Sell	11,400 -20,600	-64%	-$195K	﹤0.01%	3633
2024 Q4	$344K	Buy	+32,000	New	+$246K	﹤0.01%	3314
2024 Q3	–	Sell	-75,900	Closed	-$320K	–	5275
2024 Q2	$320K	Sell	75,900 -4,800	-6%	-$19.4K	﹤0.01%	3920
2024 Q1	$411K	Buy	80,700 +69,200	+602%	+$390K	﹤0.01%	3374
2023 Q4	$107K	Buy	+11,500	New	+$79.2K	﹤0.01%	4019
2023 Q3	–	Sell	-9,500	Closed	-$77.2K	–	4852
2023 Q2	$77.2K	Sell	9,500 -20,100	-68%	-$172K	﹤0.01%	3508
2023 Q1	$254K	Buy	+29,600	New	+$295K	﹤0.01%	2263

Other funds holding AVXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $7.85B AUM 20.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Walleye Capital's AVXL Position: Q1 2026 in Review

Walleye Capital reduced its Anavex Life Sciences (AVXL) stake by 93% in Q1 2026, selling an estimated $24.3K and leaving 398 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #4257.

Walleye Capital first reported a position in AVXL in Q4 2025 and has held it in 2 quarters since. The position peaked at $21.4K in Q4 2025. 190 funds tracked by Wall St. Rank hold AVXL as of Q1 2026.

Walleye Capital held 398 shares of Anavex Life Sciences worth $1.22K as of Q1 2026.
Walleye Capital sold 5,611 Anavex Life Sciences shares in Q1 2026, an estimated $24.3K.
Anavex Life Sciences made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #4257 holding.
Walleye Capital first reported a position in Anavex Life Sciences in Q4 2025 and has held it in 2 quarters since.
Walleye Capital's Anavex Life Sciences position peaked at $21.4K in Q4 2025.
190 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.